DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Thoraxonkologie » Nicht-kleinzelliges Lungenkarzinom

Alle Linien

CEGF816X2102
The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced EGFR-mutant NSCLC. (Aktiv)

CNIR178X2201
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

CPDR001X2X01B
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (Aktiv)

DRA-104-001
First-in-human (FIH) study of DRP-104 as single agent and in combination with atezolizumab in patients with advanced solid tumors. (Aktiv)

Helsinn ANAM Cachexia
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (Aktiv)

INKA-Studie
Ionentherapie bei nicht-kleinzelligen Pancoast-Tumoren im trimodalen Behandlungskonzept (Aktiv)

LIBRETTO-201
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation (Aktiv)

MAGELLAN
Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location (Aktiv)

MASTERKEY-318
This is a phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. (Aktiv)

MK-3475-587
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)

STARTRK-2
Studie der Phase II zu Entrectinib bei Patienten soliden Tumoren, die ein NTRK1/2/3-, ROS1- oder ALK-Gen-Rearrangement aufweisen (Aktiv)

SenPET
Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)

Trident-1
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Aktiv)

UC02-PSMA-01
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (Aktiv)

Erstlinie

ABP
Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (Aktiv)

ADAURA
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (Aktiv)

B-FAST
A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: blood-first assay screening trial) (Aktiv)

BLU-667-2303
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC (Aktiv)

BNT411-01
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (Aktiv)

BO42592
A Phase II study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin (Aktiv)

CA209-77T
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (Aktiv)

CA20973L
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) (Aktiv)

CRISP
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (Aktiv)

DESTINY-Lung04
Eine offene, randomisierte, multizentrische Phase-III-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Trastuzumab Deruxtecan (T-DXd) im Vergleich zu Chemotherapie plus Pembrolizumab für die Erstlinienbehandlung von fortgeschrittenem/metastasiertem nicht-squamösem nicht-kleinzelligem Lungenkrebs mit HER2 Exon 19 oder 20 Mutation (Aktiv)

ESPADURVA
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA) (Aktiv)

GEM3PSCA-01
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (Aktiv)

GO41717
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (Aktiv)

GSK 213400 (ZEAL-1L)
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) (Aktiv)

IReP
immune signature profiling for predicting response in patients with NSCLC to neoadjuvant ATEZOLIZUMAB plus Carboplatin/Nab Paclitaxe (Aktiv)

Keynote867
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) (Aktiv)

LCNEC-ALPINE
A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)

LIBRETTO-431
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) (Aktiv)

LIBRETTO-432 (J2G-MC-JZJX)
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (Aktiv)

MK-7339-012
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) (Aktiv)

MK-7684A-003
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003) (Aktiv)

MX39795 CUPISCO
A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapy (Aktiv)

NEOpredict (CA224-063)
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (Aktiv)

PACE-LUNG
Phase II Studie zu zusätzlicher Chemotherapie bei EGFR-positivem nicht-kleinzelligem Lungenkrebs (Aktiv)

PACIFIC-4
Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4) (Aktiv)

PAPILLON
A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Aktiv)

PDC-Lung-101
Phase I/II Studie zum Krebsimpfstoff PDC*lung01 als Erstlinientherapie bei nichtkleinzelligem Lungenkarzinom (Aktiv)

PRONTOX
Protonenbehandlung zur primären Radiochemotherapie bei fortgeschrittenen Nicht-kleinzelligen Bronchialkarzinomen (Aktiv)

TAK-788-3001
TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (Aktiv)

TRADE-hypo
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (Aktiv)

Zweitlinie oder später

1432-0001
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (Aktiv)

AIO-YMO/TRK-0415 - FORCE
Förderung der Wirksamkeit einer anti-PD-1-Behandlung (Immuntherapie Nivolumab) in Kombination mit Strahlentherapie zur Behandlung des fortgeschrittenen nicht-kleinzelligen Lungenkarzinoms (NSCLC) - FORCE (Aktiv)

ATRi_Bay–Studie
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug (Aktiv)

AZ HUDSON
Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy. (Aktiv)

Achilles ATX-NS-001
An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer (Aktiv)

BIOLUMA
trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer (Aktiv)

BMS CA224-020
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. (Aktiv)

Bayer AhRi BAY 2416964
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer (Aktiv)

BoB Module 1
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)

CA022-001
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors (Aktiv)

CANFOUR
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) (Aktiv)

CEGF816X2201C
To determine the efficacy and safety of Nivolumab in combination with EGF816 and of Nivolumab in combination with INC280 in previously treated NSCLC patients (Aktiv)

CHRYSALIS
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (Aktiv)

COMPEL
Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie mit Platin plus Pemetrexed-Chemotherapie plus Osimertinib im Vergleich zu Platin plus Pemetrexed-Chemotherapie plus Placebo bei Patienten mit EGFRm, lokal fortgeschrittenem oder metastasiertem NSCLC, die nach einer Osimertinib-Erstlinientherapie extrakraniell fortgeschritten sind (COMPEL) (Aktiv)

COSTAR LUNG
Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (Aktiv)

CTNO155B12101
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (Aktiv)

DS Tropion Lung 01
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (Aktiv)

EATON
The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D) for a continuous treatment with EGF816 and trametinib in patients with epithelial growth factor receptor (EGFR) p.T790M-positive resistance to EGFR inhibition. (Aktiv)

FIND
FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) (Aktiv)

GEM3PSCA-01
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (Aktiv)

GSK ICOS
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants (Aktiv)

Herthena-Lung01
Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC (Aktiv)

IOV-LUN-202
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer (Aktiv)

ImmunoSABR Phase 2 trial
Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer (Aktiv)

L-AP-IS Lunge
L-AP-IS: Lung cancer, Ablative high Precision radiotherapy and the Immune System: Evaluation of the immune-modulatory effects of stereotactic body radiation therapy (SBRT) of pulmonary lesions (Aktiv)

LIBRETTO-001
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)

LOXO-TRK-15002
Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3. (Aktiv)

LOXO-TRK-15003
A Phase 1/2 Clinical Trial of Pediatric Cancer Patients With Solid Tumors Treated with LOXO-101 (Aktiv)

MCLA-128-CL01/MERUS
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)

MS200095-0031
A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC). (Aktiv)

MS200095-031 Insight 2
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (Aktiv)

Novartis CDKY709A12101C
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC (Aktiv)

RAGNAR
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (Aktiv)

RadImmun-NSCLC
Evaluierung von systemischen Effekten der kombinierten palliativen Strahlen- und Immuntherapie bei nicht kleinzelligem Bronchialkarzinom nach unzureichendem Ansprechen auf Immun-Checkpoint-Inhibitoren (Aktiv)

SORATRAM
Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)

Sanofi CARMEN
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (Aktiv)

Skyscraper-03 GO41854
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de